Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
difluoromethylornithine + celecoxib + cyclophosphamide + topotecan
- Development stage
- Unknown
- Lead developer
- New Advances in Neuroblastoma Therapy Consortium
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This therapeutic regimen is an experimental combination therapy being evaluated for the treatment of relapsed or refractory high-risk neuroblastoma. The combination consists of **difluoromethylornithine (DFMO)**, an irreversible inhibitor of ornithine decarboxylase (ODC) that depletes intracellular polyamines; **celecoxib**, a selective cyclooxygenase-2 (COX-2) inhibitor; and a cytotoxic chemotherapy backbone of **cyclophosphamide** (an alkylating agent) and **topotecan** (a topoisomerase I inhibitor). The rationale for this combination is based on the observation that polyamine synthesis and COX-2 pathways are often upregulated in neuroblastoma and contribute to tumor progression and chemoresistance. By targeting these metabolic and inflammatory pathways alongside standard DNA-damaging agents, the regimen aims to overcome resistance and improve clinical outcomes in pediatric patients with difficult-to-treat neuroblastoma.
- Other names
- DFMO + celecoxib + cyclophosphamide + topotecanEflornithine + celecoxib + cyclophosphamide + topotecan
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TOP1 (DNA Topoisomerase I)DNAODC1 (Ornithine decarboxylase)
Beyond the preview
Go deeper on difluoromethylornithine + celecoxib + cyclophosphamide + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on difluoromethylornithine + celecoxib + cyclophosphamide + topotecan.